Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.55 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.55 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
| ▸ | TP53 | P04637 | 3/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | CASP6 | P55212 | 1/20 | 0.43 |
| ▸ | RARA | P10276 | 1/20 | 0.42 |
| ▸ | RARB | P10826 | 1/20 | 0.42 |
| ▸ | WDR5 | P61964 | 1/20 | 0.41 |
| ▸ | FABP4 | P15090 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.40 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL70539 | 0.89 | PDE4D (0.47) | TSHRHSD17B10TP53LMNARARA | |
| SCHEMBL15878229 | 0.83 | TSHR (0.53) | TSHRHSD17B10CYP3A4TP53GAA | |
| SCHEMBL73150 | 0.82 | RARA (0.49) | TP53RARARARBKMT2AMEN1 | |
| SCHEMBL9701370 | 0.81 | TSHR (0.59) | TSHRHSD17B10CYP3A4TP53LMNA | |
| SCHEMBL13579888 | 0.79 | TSHR (0.55) | TSHRHSD17B10CYP3A4TP53L3MBTL1 | |
| SCHEMBL14316273 | 0.79 | RARB (0.52) | TP53RARARARBFABP4 | |
| SCHEMBL3540950 | 0.79 | TSHR (0.53) | TSHRHSD17B10CYP3A4TP53GAA | |
| SCHEMBL26031210 | 0.78 | TSHR (0.51) | TSHRHSD17B10CYP3A4TP53GAA | |
| SCHEMBL4601086 | 0.77 | PTPN11 (0.56) | TSHRHSD17B10GAAL3MBTL1RARA | |
| SCHEMBL2583219 | 0.77 | LCK (0.46) | TSHRHSD17B10LMNARARARARB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100240677-A1 | Compounds as PDE IV and TNF Inhibitors | AVENTIS PHARMA LIMITED (GB) | 2010-09-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100240677-A1 | Compounds as PDE IV and TNF Inhibitors | PDE4A, PDE4B, PDE7A | TSHR 1209/4885HSD17B10 1544/4885CYP3A4 870/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.